Lantheus (LNTH) Stock: Buy, Sell, or Hold?
LNTH - Lantheus Holdings, Inc
$99.65
0.12 (0.12%)
▲
5d:
-0.07%
30d:
-1.22%
90d:
-9.32%
HOLD
LOW Confidence
Analysis Updated: Oct 1, 2026 12:00 AM ET
Earnings: Nov 05, 2026
Get Alerted When LNTH Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: LNTH shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: LNTH shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$136.70
Based on 9.0% avg growth
INTRINSIC VALUE TODAY
$84.88
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 14.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: LNTH is currently trading at $99.65, which is considered oversold relative to its 30-day fair value range of $99.97 to $100.89. From a valuation perspective, the stock is trading at a premium (Forward PE: 15.6) compared to its historical average (14.0). At these levels, the market is pricing in 3.7% annual earnings growth.
Technical Outlook: Technically, LNTH is in a strong downtrend. The price is currently testing key support at $99.31. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: LNTH scores 68/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, LNTH is in a strong downtrend. The price is currently testing key support at $99.31. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: LNTH scores 68/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$99.97 -
$100.89
Company Quality Score
55/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
89.0%
Protect Your Profits
Holding LNTH? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (68/100)
- BULLISH: High volume confirmation
- NEUTRAL: Near Wall St target ($107.74)
- BULLISH: Expecting earnings turnaround to 3.7% growth with 2.7% revenue growth
- CAUTION: Bottoming setup, but lagging the sector by 13% over 20 days — wait for relative strength
Trading Range Analysis
30-Day Trading Range
$99.97 -
$100.89
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$99.31
Resistance Level
$100.96
Current Trend
Strong Downtrend
Technical data as of
Oct 1, 2026
Fundamental Context
Forward P/E (Next Year Est.)
15.63
Wall Street Target
$107.74
(+8.1%)
Revenue Growth (YoY)
2.7%
Earnings Growth (YoY)
-0.9%
Profit Margin
17.7%
Valuation Premium vs History
+3.7% premium
PE vs Historical
15.6 vs 14.0
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+3.7%
(market-implied from PE analysis)
1-Year Target
$103.34
(+4%)
2-Year Target
$107.16
(+8%)
3-Year Target
$111.13
(+12%)
3-Yr Target (if PE normalizes)
(PE: 16→14)
PE COMPRESSION
$99.56
(0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 20.4, Growth: 13.9%)
$192.14
(+93%)
Base:
(SPY PE: 15.6, Growth: 13.9%)
$147.17
(+48%)
Bear:
(PE: 13.3, Growth: 13.9%)
$125.10
(+26%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (24x PE), but valuation improves significantly next year (16x PE) as earnings recover.
Trailing PE: 23.81 | Current EPS (TTM): $4.18
Bull Case
$167.03
(+68%)
Analyst growth 52.6%, PE expands to 26.2
Base Case
$151.85
(+52%)
Market implied 52.6%, PE stable at 23.8
Bear Case
$67.68
(-32%)
Severe decline -20.0%, PE contracts to 20.2
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: October 01, 2026 9:05 PM ET
Data refreshes hourly during market hours. Next update: 10:05 PM
Data refreshes hourly during market hours. Next update: 10:05 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is LNTH showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$208 | 54 HOLD |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$96 | 58 HOLD |
|
AQST
Aquestive Therapeutics I… |
STRONG BUY
9 analysts |
$9 | 62 BUY |
|
BCRX
BioCryst Pharmaceuticals… |
STRONG BUY
12 analysts |
$21 | 53 HOLD |
|
ALKS
Alkermes Plc |
BUY
15 analysts |
$57 | 63 BUY |
Advanced LNTH Option Strategies
Professional options setups generated by AI based on today's LNTH price and gamma walls.
